Editas Medicine Company Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.

It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.

In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer.

It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases.

The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.

Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine, Inc.

Country	United States
Founded	2013
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	265
CEO	Gilmore O’Neill

Contact Details

Address: 11 Hurley Street Cambridge, Delaware 02141 United States
Phone	617 401 9000
Website	editasmedicine.com

Stock Details

Ticker Symbol	0IFK
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US28106W1036
SIC Code	2836

Key Executives

Name	Position
Gilmore O’Neill	Chief Executive Officer
Erick Lucera	Chief Financial Officer
Cristi Barnett	Head of Investor Relations